Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › gastric adenocarcinoma

Gastric adenocarcinoma

Part of Cancer

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for gastric adenocarcinoma

30 trials tracked for gastric adenocarcinoma: 6 in phase 3 or 4 and 3 with published results. The most-cited published study has 446 citations.

30Trials tracked
6Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 6 Phase 2 20 Phase 1 4
  1. Phase 3 Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) Completed · 446 cited
  2. Phase 3 A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) Completed · 168 cited
  3. Phase 3 A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer Completed · 98 cited
  4. Phase 3 Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Completed
  5. Phase 3 A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer Completed
  6. Phase 3 Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer Completed
Show 24 more trials
  1. Phase 2 PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies Completed
  2. Phase 2 A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059) Completed
  3. Phase 2 Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer Completed
  4. Phase 2 Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer Completed
  5. Phase 2 A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer Completed
  6. Phase 2 Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma Completed
  7. Phase 2 Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer Completed
  8. Phase 2 Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction Completed
  9. Phase 2 Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology Completed
  10. Phase 2 Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer Completed
  11. Phase 2 Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer Completed
  12. Phase 2 Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas Completed
  13. Phase 2 Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers Completed
  14. Phase 2 A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer Completed
  15. Phase 2 Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Completed
  16. Phase 2 TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Completed
  17. Phase 2 Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma Completed
  18. Phase 2 Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis Completed
  19. Phase 2 A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer Completed
  20. Phase 2 Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer Completed
  21. Phase 1 A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer Completed
  22. Phase 1 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Completed
  23. Phase 1 TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma Completed
  24. Phase 1 DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein Completed

Showing the 30 most-cited and recently-updated of 30 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Gastric adenocarcinoma: what the trials found

In patients with gastric adenocarcinoma, pembrolizumab combination therapy demonstrated statistically significant improvements in Progression-Free Survival (PFS) and Overall Survival (OS) for participants with a PD-L1 CPS ≥1 1. However, OS did not reach statistical significance in the subgroup of patients with a PD-L1 CPS ≥10 1. In another trial involving pembrolizumab in PD-L1 positive participants, while OS showed a statistically significant improvement over the control 2, the PFS did not reach statistical significance 2.

Ramucirumab demonstrated superior Progression-Free Survival (PFS) compared to standard of care 3 and achieved an Objective Response Rate (ORR) of 26.5% vs 21.9% in a Phase 3 trial 3. In a separate Phase 2 study, Ramucirumab showed ORRs of 27.6% and 25.4% across different dosage arms with reported PFS values of approximately 5.16 to 5.42 months 21.

Andecaliximab was evaluated in two trials; one Phase 3 trial showed a statistically significant improvement in Objective Response Rate (ORR) but did not reach statistical significance for Overall Survival (OS) or Progression-Free Survival (PFS) 6. A separate Phase 2 trial of Andecaliximab did not show statistically significant differences in ORR, PFS, or OS compared to the control 19.

Other investigated agents include tucatinib, which showed a mean maximum percentage change from baseline in weight of 0.34% vs 6.21% 4, and Rivoceranib, which was associated with specific changes in quality of life scores (EORTC QLQ-STO22) and visual analog scales (EQ-5D-5L) 5. Cisplatin was evaluated in multiple trials [7, 9].

Recent results — preliminary, needs further review

  • Cellvizio Real-Time In Vivo Cellular Imaging Platform with Confocal Miniprobes (not yet corroborated)
  • Irinotecan toxicity and tolerability (not yet corroborated)
  • Oxaliplatin grade 3-4 treatment-related adverse events (not yet corroborated)
  • TAS 102 (not yet corroborated)
  • PDR001+LAG521 clinical benefit rate (not yet corroborated)

For the clinician treating this condition

  • Pembrolizumab combination therapy shows statistically significant improvements in PFS and OS specifically in patients with PD-L1 CPS ≥1.
  • Ramucirumab is associated with improved Progression-Free Survival (PFS) and established Objective Response Rates (ORR) exceeding 25% in multiple trials.
  • Andecaliximab results are mixed; while one trial showed a significant improvement in ORR, another did not show statistically significant differences across primary endpoints.

AI synthesis of 8 cited trials, updated Jun 28, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Immune checkpoint inhibitor and chemotherapy combination improves pathological response in gastric adenocarcinoma
Allergy & Immunology Meta-analysis
Immune checkpoint inhibitor and chemotherapy combination improves pathological response in gastric adenocarcinoma Immune therapy combined with chemotherapy improves gastric cancer outcomes
This systematic review and meta-analysis of 74 trials evaluates neoadjuvant and perioperative strategies for locally advanced gastric and ga…
Adding immune checkpoint inhibitors to chemotherapy can significantly improve response rates and survival for patients with advanced stomach…
Frontiers Sep 25, 2026
Pulmonary lymphangitic carcinomatosis may mimic interstitial lung disease in patients with gastric adenocarcinoma
Pulmonology & Critical Care Sys. Review
Pulmonary lymphangitic carcinomatosis may mimic interstitial lung disease in patients with gastric adenocarcinoma Lung cancer can mimic common lung diseases in young men
This case report and review of the literature describes a 33-year-old male with gastric adenocarcinoma and pulmonary lymphangitic carcinomat…
A 33-year-old man with a lung condition that looked like a common disease was actually a rare form of cancer.
Frontiers Sep 25, 2026
Spatial immune-ecology framework proposed for gastric and GEJ adenocarcinoma ICI selection
Oncology Guideline
Spatial immune-ecology framework proposed for gastric and GEJ adenocarcinoma ICI selection Spatial Features Help Map Immune Responses in Stomach Cancer
This narrative guideline review proposes a spatial immune-ecology framework for advanced gastric and gastroesophageal junction adenocarcinom…
New research maps how the immune system interacts with stomach and esophageal cancer to help experts understand why some treatments work bet…
Frontiers Sep 13, 2026
CLDN18.2 expression prevalence of 33.99% in patients with gastric and gastroesophageal junction adenocarcinoma
Oncology Meta-analysis
CLDN18.2 expression prevalence of 33.99% in patients with gastric and gastroesophageal junction adenocarcinoma New data shows how many stomach cancer patients have target protein
This meta-analysis of 12,173 patients with gastric or gastroesophageal junction adenocarcinoma identified a pooled prevalence of CLDN18.2 ex…
A large review helps doctors understand how many stomach cancer patients have a specific protein that could be a target for new treatments.
Sep 6, 2026
H. pylori prevalence 34.3% in French Guiana; gastric adenocarcinoma found in 1.65%
Rheumatology Cohort
H. pylori prevalence 34.3% in French Guiana; gastric adenocarcinoma found in 1.65% One Third of Stomach Tests Show Hidden Bacteria Risk
A retrospective cohort study of 545 patients with H.
A new look at stomach biopsies shows one in three patients carry a hidden bacteria that can lead to serious disease.
Frontiers Apr 28, 2026

Research across Cancer

Related studies from across the Cancer family.

miR-155 overexpression is frequently associated with treatment resistance across 8 cancer types
Drug Pipeline Meta-analysis
miR-155 overexpression is frequently associated with treatment resistance across 8 cancer types miR-155 Expression Linked to Treatment Resistance in Various Cancers
This systematic review of 19 studies across 8 cancer types indicates that miR-155 overexpression is associated with treatment resistance in …
Research suggests that high levels of a specific molecule, miR-155, may be linked to how well certain cancers respond to treatment.
Frontiers Oct 21, 2026
Zanidatamab with chemotherapy or tislelizumab achieves 70% objective response rate in HER2-positive gastroesophageal adenocarcinoma
Oncology Meta-analysis
Zanidatamab with chemotherapy or tislelizumab achieves 70% objective response rate in HER2-positive gastroesophageal adenocarcinoma New drug combination shows promise for advanced stomach cancer
This meta-analysis of 685 patients with advanced HER2-positive gastroesophageal adenocarcinoma found that zanidatamab combined with chemothe…
A new drug combination shows a 70% response rate for patients with a specific type of advanced stomach cancer, though it carries some risks.
Oct 16, 2026
Long-Surviving PDAC With HRR Alterations May Face CNS Sanctuary Relapse
Rheumatology Sys. Review
Long-Surviving PDAC With HRR Alterations May Face CNS Sanctuary Relapse Long Survival in Pancreatic Cancer Can Bring Brain Spread
This case report describes a 51-year-old man with metastatic pancreatic ductal adenocarcinoma who survived 30 months from diagnosis and 3.5 …
A single case shows pancreatic cancer that responds to treatment may later reach the brain, even after 30 months.
Frontiers Oct 12, 2026
Fungal dysbiosis is associated with altered community structures and immune remodeling in several gastrointestinal cancers
Gastroenterology Sys. Review
Fungal dysbiosis is associated with altered community structures and immune remodeling in several gastrointestinal cancers Fungi may play a role in several types of cancer
This narrative review synthesizes evidence regarding fungal dysbiosis in colorectal cancer, gastric cancer, and pancreatic ductal adenocarci…
New research explores how fungal imbalances in the body might link to colorectal, gastric, and pancreatic cancers.
Frontiers Oct 8, 2026
NALIRIFOX shows no significant difference in overall survival compared to FOLFIRINOX in pancreatic cancer
Oncology Meta-analysis
NALIRIFOX shows no significant difference in overall survival compared to FOLFIRINOX in pancreatic cancer NALIRIFOX Shows Similar Survival Rates to FOLFIRINOX for Pancreatic Cancer
This meta-analysis of reconstructed individual patient data evaluated NALIRIFOX versus FOLFIRINOX and mFOLFIRINOX in treatment-naïve patient…
A new analysis shows NALIRIFOX offers similar survival rates to FOLFIRINOX for advanced pancreatic cancer while having different side effect…
Frontiers Sep 19, 2026
MDT-guided perioperative strategy and staged anticoagulation manage pancreatic cancer in a patient with Moyamoya disease
Oncology Guideline
MDT-guided perioperative strategy and staged anticoagulation manage pancreatic cancer in a patient with Moyamoya disease Multidisciplinary Strategy Helps Manage Moyamoya Disease and Pancreatic Cancer
This case report describes a multidisciplinary team-guided perioperative strategy for a patient with Moyamoya disease and pancreatic ductal …
A specialized surgical strategy helped a patient with both Moyamoya disease and pancreatic cancer undergo surgery without any neurological c…
Frontiers Sep 14, 2026
Splenic hilum nodal involvement is rare in pancreatic body adenocarcinoma with a 1.1% prevalence
Oncology Meta-analysis
Splenic hilum nodal involvement is rare in pancreatic body adenocarcinoma with a 1.1% prevalence Nodal Involvement Near the Spleen Linked to Pancreatic Cancer
This meta-analysis of 2260 patients evaluates the prevalence of splenic hilum and splenic artery nodal involvement in pancreatic ductal aden…
New data shows that while certain lymph nodes near the spleen are often involved in pancreatic cancer, they may not change survival outcomes…
Sep 12, 2026
Local therapies for liver, lung, and locoregional recurrence improve survival in pancreatic ductal adenocarcinoma
Gastroenterology Meta-analysis
Local therapies for liver, lung, and locoregional recurrence improve survival in pancreatic ductal adenocarcinoma Local Treatments May Improve Survival for Patients with Recurring Pancreatic Cancer
This meta-analysis of 22 studies evaluated local therapies versus conventional management for single-site recurrent pancreatic ductal adenoc…
New data suggests that local treatments like surgery can significantly improve survival for patients whose pancreatic cancer has returned.
Sep 1, 2026
MULTIPL biomarker identifies patients with significantly longer overall survival on gemcitabine plus nab-paclitaxel
Oncology RCT
MULTIPL biomarker identifies patients with significantly longer overall survival on gemcitabine plus nab-paclitaxel Trial Shows Biomarker Helps Identify Best Treatment for Pancreatic Cancer
This randomized Phase II trial and training cohort evaluated the MULTIPL biomarker in 160 and 268 patients with metastatic pancreatic ductal…
A new biomarker tool may help doctors choose the most effective chemotherapy for patients with metastatic pancreatic cancer.
medRxiv Aug 28, 2026
KRAS G12C inhibitors may remodel immunosuppressive tumor microenvironments into immunostimulatory states in KRAS-mutant tumors
Oncology Sys. Review
KRAS G12C inhibitors may remodel immunosuppressive tumor microenvironments into immunostimulatory states in KRAS-mutant tumors Targeted Drugs May Help Change Immune Environment in KRAS Tumors
This mini-review examines the impact of KRAS mutations and G12C inhibitors on the tumor immune microenvironment across PDAC, CRC, and LAC. T…
New research suggests that specific drugs targeting KRAS mutations may help reshape the immune environment around certain types of cancer.
Frontiers Aug 27, 2026
CXRT improves survival and disease-free rates specifically in node-negative pancreatic head adenocarcinoma patients
Oncology RCT
CXRT improves survival and disease-free rates specifically in node-negative pancreatic head adenocarcinoma patients Radiotherapy shows promise for specific pancreatic cancer patients
This Phase III multicenter randomized controlled trial of 354 patients with adenocarcinoma of the pancreatic head found no significant diffe…
Adding radiation to chemotherapy may improve survival and stay disease-free for certain patients with pancreatic head cancer.
Aug 22, 2026
Immune checkpoint inhibitors show limited activity in unselected pancreatic ductal adenocarcinoma without specific biomarkers
Allergy & Immunology Sys. Review
Immune checkpoint inhibitors show limited activity in unselected pancreatic ductal adenocarcinoma without specific biomarkers New Strategies Target Immune Therapies for Pancreatic Cancer
This mini review examines the role of immune checkpoint blockade, vaccines, and cellular therapies in recurrent pancreatic ductal adenocarci…
New research highlights specific ways to better select patients for immune checkpoint inhibitors and advanced cell therapies in pancreatic c…
Frontiers Aug 14, 2026

Questions about gastric adenocarcinoma

What is the prevalence of CLDN18.2 expression in gastric adenocarcinoma patients?

CLDN18.2 is found in roughly 30% to 34% of gastric adenocarcinoma patients when using the stricter clinical cutoff, though rates vary by threshold and population [4][6].

Full answer →
Does combining chemotherapy and immune checkpoint inhibitors improve response in gastric adenocarcinoma?

Yes. Adding immune checkpoint inhibitors to chemotherapy improves pathological response rates in gastric adenocarcinoma, though the survival benefit is less consistent.

Full answer →
Is there a link between H. pylori and gastric adenocarcinoma in French Guiana?

Yes. A 2023 study at Cayenne Hospital in French Guiana found H. pylori in 34.3% of patients tested, and H. pylori is a well-established major risk factor for gastric adenocarcinoma [5][6][8].

Full answer →